Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

The role of the Birt-Hogg-Dubé protein in mTOR activation and renal tumorigenesis.

Hartman TR, Nicolas E, Klein-Szanto A, Al-Saleem T, Cash TP, Simon MC, Henske EP.

Oncogene. 2009 Apr 2;28(13):1594-604. doi: 10.1038/onc.2009.14. Epub 2009 Feb 23.

2.

The Birt-Hogg-Dube and tuberous sclerosis complex homologs have opposing roles in amino acid homeostasis in Schizosaccharomyces pombe.

van Slegtenhorst M, Khabibullin D, Hartman TR, Nicolas E, Kruger WD, Henske EP.

J Biol Chem. 2007 Aug 24;282(34):24583-90. Epub 2007 Jun 7.

3.

Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys.

Baba M, Furihata M, Hong SB, Tessarollo L, Haines DC, Southon E, Patel V, Igarashi P, Alvord WG, Leighty R, Yao M, Bernardo M, Ileva L, Choyke P, Warren MB, Zbar B, Linehan WM, Schmidt LS.

J Natl Cancer Inst. 2008 Jan 16;100(2):140-54. doi: 10.1093/jnci/djm288. Epub 2008 Jan 8.

4.

Renal tumour suppressor function of the Birt-Hogg-Dubé syndrome gene product folliculin.

Hudon V, Sabourin S, Dydensborg AB, Kottis V, Ghazi A, Paquet M, Crosby K, Pomerleau V, Uetani N, Pause A.

J Med Genet. 2010 Mar;47(3):182-9. doi: 10.1136/jmg.2009.072009. Epub 2009 Oct 19.

PMID:
19843504
5.

Deficiency of FLCN in mouse kidney led to development of polycystic kidneys and renal neoplasia.

Chen J, Futami K, Petillo D, Peng J, Wang P, Knol J, Li Y, Khoo SK, Huang D, Qian CN, Zhao P, Dykema K, Zhang R, Cao B, Yang XJ, Furge K, Williams BO, Teh BT.

PLoS One. 2008;3(10):e3581. doi: 10.1371/journal.pone.0003581. Epub 2008 Oct 30. Erratum in: PLoS ONE. 2008;3(11). doi: 10.1371/annotation/0f06471c-1993-4144-b785-d58924ac0b5c. PLoS ONE. 2008;3(11). doi: 10.1371/annotation/136385d5-b241-4ecc-b31a-6dea3ebf3bc4. Dykyma, Karl [corrected to Dykema, Karl].

6.

Pulmonary cysts of Birt-Hogg-Dubé syndrome: a clinicopathologic and immunohistochemical study of 9 families.

Furuya M, Tanaka R, Koga S, Yatabe Y, Gotoda H, Takagi S, Hsu YH, Fujii T, Okada A, Kuroda N, Moritani S, Mizuno H, Nagashima Y, Nagahama K, Hiroshima K, Yoshino I, Nomura F, Aoki I, Nakatani Y.

Am J Surg Pathol. 2012 Apr;36(4):589-600. doi: 10.1097/PAS.0b013e3182475240.

PMID:
22441547
7.

Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2.

Hasumi Y, Baba M, Ajima R, Hasumi H, Valera VA, Klein ME, Haines DC, Merino MJ, Hong SB, Yamaguchi TP, Schmidt LS, Linehan WM.

Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18722-7. doi: 10.1073/pnas.0908853106. Epub 2009 Oct 22.

8.

Birt-Hogg-Dubé syndrome: Clinical and molecular aspects of recently identified kidney cancer syndrome.

Hasumi H, Baba M, Hasumi Y, Furuya M, Yao M.

Int J Urol. 2016 Mar;23(3):204-10. doi: 10.1111/iju.13015. Epub 2015 Nov 25. Review.

9.

Renal angiomyolipoma in Birt-Hogg-Dube syndrome: A case study supporting overlap with tuberous sclerosis complex.

Dow E, Winship I.

Am J Med Genet A. 2016 Dec;170(12):3323-3326. doi: 10.1002/ajmg.a.37952. Epub 2016 Sep 19.

PMID:
27643397
10.

Expression of Birt-Hogg-Dubé gene mRNA in normal and neoplastic human tissues.

Warren MB, Torres-Cabala CA, Turner ML, Merino MJ, Matrosova VY, Nickerson ML, Ma W, Linehan WM, Zbar B, Schmidt LS.

Mod Pathol. 2004 Aug;17(8):998-1011.

11.

Interaction of folliculin (Birt-Hogg-Dubé gene product) with a novel Fnip1-like (FnipL/Fnip2) protein.

Takagi Y, Kobayashi T, Shiono M, Wang L, Piao X, Sun G, Zhang D, Abe M, Hagiwara Y, Takahashi K, Hino O.

Oncogene. 2008 Sep 11;27(40):5339-47. doi: 10.1038/onc.2008.261. Epub 2008 Jul 28.

PMID:
18663353
12.

Loss of the Birt-Hogg-Dubé tumor suppressor results in apoptotic resistance due to aberrant TGFβ-mediated transcription.

Cash TP, Gruber JJ, Hartman TR, Henske EP, Simon MC.

Oncogene. 2011 Jun 2;30(22):2534-46. doi: 10.1038/onc.2010.628. Epub 2011 Jan 24.

13.

Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling.

Baba M, Hong SB, Sharma N, Warren MB, Nickerson ML, Iwamatsu A, Esposito D, Gillette WK, Hopkins RF 3rd, Hartley JL, Furihata M, Oishi S, Zhen W, Burke TR Jr, Linehan WM, Schmidt LS, Zbar B.

Proc Natl Acad Sci U S A. 2006 Oct 17;103(42):15552-7. Epub 2006 Oct 6.

14.

Absence of the Birt-Hogg-Dubé gene product is associated with increased hypoxia-inducible factor transcriptional activity and a loss of metabolic flexibility.

Preston RS, Philp A, Claessens T, Gijezen L, Dydensborg AB, Dunlop EA, Harper KT, Brinkhuizen T, Menko FH, Davies DM, Land SC, Pause A, Baar K, van Steensel MA, Tee AR.

Oncogene. 2011 Mar 10;30(10):1159-73. doi: 10.1038/onc.2010.497. Epub 2010 Nov 8.

15.

Tumor suppressor FLCN inhibits tumorigenesis of a FLCN-null renal cancer cell line and regulates expression of key molecules in TGF-beta signaling.

Hong SB, Oh H, Valera VA, Stull J, Ngo DT, Baba M, Merino MJ, Linehan WM, Schmidt LS.

Mol Cancer. 2010 Jun 23;9:160. doi: 10.1186/1476-4598-9-160.

16.

Unique mutation, accelerated mTOR signaling and angiogenesis in the pulmonary cysts of Birt-Hogg-Dubé syndrome.

Nishii T, Tanabe M, Tanaka R, Matsuzawa T, Okudela K, Nozawa A, Nakatani Y, Furuya M.

Pathol Int. 2013 Jan;63(1):45-55. doi: 10.1111/pin.12028. Epub 2013 Jan 18.

PMID:
23356225
17.
18.

Distinctive expression patterns of glycoprotein non-metastatic B and folliculin in renal tumors in patients with Birt-Hogg-Dubé syndrome.

Furuya M, Hong SB, Tanaka R, Kuroda N, Nagashima Y, Nagahama K, Suyama T, Yao M, Nakatani Y.

Cancer Sci. 2015 Mar;106(3):315-23. doi: 10.1111/cas.12601. Epub 2015 Feb 17.

19.

Novel mutations in the BHD gene and absence of loss of heterozygosity in fibrofolliculomas of Birt-Hogg-Dubé patients.

van Steensel MA, Verstraeten VL, Frank J, Kelleners-Smeets NW, Poblete-Gutiérrez P, Marcus-Soekarman D, Bladergroen RS, Steijlen PM, van Geel M.

J Invest Dermatol. 2007 Mar;127(3):588-93. Epub 2006 Nov 23.

20.

The folliculin-FNIP1 pathway deleted in human Birt-Hogg-Dubé syndrome is required for murine B-cell development.

Baba M, Keller JR, Sun HW, Resch W, Kuchen S, Suh HC, Hasumi H, Hasumi Y, Kieffer-Kwon KR, Gonzalez CG, Hughes RM, Klein ME, Oh HF, Bible P, Southon E, Tessarollo L, Schmidt LS, Linehan WM, Casellas R.

Blood. 2012 Aug 9;120(6):1254-61. doi: 10.1182/blood-2012-02-410407. Epub 2012 Jun 18.

Supplemental Content

Support Center